Special Issue "Cancer: Novel Approaches in the Discovery and Design of Targeted Therapies"
Deadline for manuscript submissions: 31 December 2021.
Efforts to discover drugs that can cure cancers are continuing. Tyrosine kinase inhibitors, such as imatinib, represent a significant achievement for the treatment of chronic myelogenous leukemia with a BCR-ABL translocation. BCR-ABL has a strong oncogenic effect and represents a good target for inhibition; therefore, finding oncogenic molecules is a straightforward way to find molecular targets. However, inhibitors for strong oncogenes, such as MYC and RAS, are not used at the clinical phage. Improved chemical approaches or other regulators of these genes await discovery. By contrast, molecular targets can be found using a variety of strategies. Comprehensive screening is one promising approach for identifying new oncogenic targets of cancer cell survival. The recent development of CRISPR screening now provides a powerful tool for finding essential molecules relevant to cancers. A CRISPR library can identify essential cancer-specific molecules that could also be therapeutic targets. CRISPR screenings with novel modified methods have revealed synergistic and synthetic lethal combinations of drugs. In addition, a CRISPR library can induce drug resistance by random mutation, and this would be useful for overcoming the serious concerns of drug resistance. This Special Issue focuses on studies related to basic strategies and comprehensive screening for molecular targets for cancer cures. Up-to-date review articles and commentaries are also welcome.
Dr. Morito Kurata
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Molecular Targeted therapy
- Drug resisntance
- CRISPR screening
- Synthetic lethal
- Synergistic drug